Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients
Abstract Telmisartan, a new angiotensin II type 1 receptor blocker (ARB), was recently reported to stimulate PPARγ, and stronger effects of Telmisartan on insulin sensitivity has been expected than the class effect of ARB. In the present study, we examined the effects of Telmisartan on insulin sensi...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2007-08, Vol.77 (2), p.210-214 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 214 |
|---|---|
| container_issue | 2 |
| container_start_page | 210 |
| container_title | Diabetes research and clinical practice |
| container_volume | 77 |
| creator | Usui, Isao Fujisaka, Shiho Yamazaki, Katsuya Takano, Atsuko Murakami, Shiho Yamazaki, Yu Urakaze, Masaharu Hachiya, Haruo Takata, Michiyo Senda, Satoko Iwata, Minoru Satoh, Akira Sasaoka, Toshiyasu AK, Norel Dim Temaru, Rie Kobayashi, Masashi |
| description | Abstract Telmisartan, a new angiotensin II type 1 receptor blocker (ARB), was recently reported to stimulate PPARγ, and stronger effects of Telmisartan on insulin sensitivity has been expected than the class effect of ARB. In the present study, we examined the effects of Telmisartan on insulin sensitivity and adipokine levels in hypertensive and type 2 diabetic patients. Outpatients with both hypertension and type 2 diabetes mellitus ( n = 36; male 23, female 13), received 20–40 mg Telmisartan orally once daily for 6 months. Physical examinations and blood or urine tests were performed before and 3 or 6 months after starting Telmisartan treatment. Results were statistically compared using Wilcoxon analysis. Telmisartan treatment for 3 or 6 months reduced systolic and diastolic blood pressure and urinary albumin excretion. Fasting plasma glucose, HbA1c, total and HDL-cholesterol, triglyceride, body weight, BMI and waist length were not changed. Fasting IRI and HOMA-IR were significantly decreased after Telmisartan treatment, suggesting the improved insulin sensitivity. Total and high molecular adiponectin were not changed. Interestingly, serum leptin was significantly increased by 3 months Telmisartan treatment, suggesting a possible involvement of leptin in improved insulin sensitivity. In conclusion, Telmisartan improved insulin resistance with increased serum leptin level in hypertensive and type 2 diabetic patients. |
| doi_str_mv | 10.1016/j.diabres.2006.11.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70459952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822707000022</els_id><sourcerecordid>70459952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c418t-ac857449c53d231e92df03f6abd873d316384ac62cda74c6e26f5edfe075ea433</originalsourceid><addsrcrecordid>eNqFkUtv1DAUha0K1E4fP6HIK3YJfiXObIqqCmilokrQri2PfUM99TjBdgbNir-O0xkJiQ2ra9nn3Ov7HYQuKakpoe2HdW2dXkVINSOkrSmtCRVHaEE7yaqOMfkGLYquez2foNOU1qQIuWiO0QmVTBAh2QL9fgS_cUnHrAOOYCcDFq_8MFg8luZpioB1sPj24et1dfcN_3L5GbtgIujkwg88ep02GnsYswulbMGXZ_y8GyFmCMlt9_5cLjDD858hO4NHnR2EnM7R2177BBeHeoaePn96vLmt7h--3N1c31dG0C5X2nSNFGJpGm4Zp7Bktie8b_XKdpJbTlveCW1aZqyWwrTA2r4B2wORDWjB-Rl6v-87xuHnBCmrsrUB73WAYUpKEtEslw0rwmYvNHFIKUKvxug2Ou4UJWomr9bqQF7N5BWlqpAvvneHAdNqA_av64C6CD7uBVDW3DqIKpmCoPB2EUxWdnD_HXH1TwfjXXBG-xfYQVoPUwyFoaIqMUXU9zn-OX0iS_KEMf4HJxmt9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70459952</pqid></control><display><type>article</type><title>Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Usui, Isao ; Fujisaka, Shiho ; Yamazaki, Katsuya ; Takano, Atsuko ; Murakami, Shiho ; Yamazaki, Yu ; Urakaze, Masaharu ; Hachiya, Haruo ; Takata, Michiyo ; Senda, Satoko ; Iwata, Minoru ; Satoh, Akira ; Sasaoka, Toshiyasu ; AK, Norel Dim ; Temaru, Rie ; Kobayashi, Masashi</creator><creatorcontrib>Usui, Isao ; Fujisaka, Shiho ; Yamazaki, Katsuya ; Takano, Atsuko ; Murakami, Shiho ; Yamazaki, Yu ; Urakaze, Masaharu ; Hachiya, Haruo ; Takata, Michiyo ; Senda, Satoko ; Iwata, Minoru ; Satoh, Akira ; Sasaoka, Toshiyasu ; AK, Norel Dim ; Temaru, Rie ; Kobayashi, Masashi</creatorcontrib><description>Abstract Telmisartan, a new angiotensin II type 1 receptor blocker (ARB), was recently reported to stimulate PPARγ, and stronger effects of Telmisartan on insulin sensitivity has been expected than the class effect of ARB. In the present study, we examined the effects of Telmisartan on insulin sensitivity and adipokine levels in hypertensive and type 2 diabetic patients. Outpatients with both hypertension and type 2 diabetes mellitus ( n = 36; male 23, female 13), received 20–40 mg Telmisartan orally once daily for 6 months. Physical examinations and blood or urine tests were performed before and 3 or 6 months after starting Telmisartan treatment. Results were statistically compared using Wilcoxon analysis. Telmisartan treatment for 3 or 6 months reduced systolic and diastolic blood pressure and urinary albumin excretion. Fasting plasma glucose, HbA1c, total and HDL-cholesterol, triglyceride, body weight, BMI and waist length were not changed. Fasting IRI and HOMA-IR were significantly decreased after Telmisartan treatment, suggesting the improved insulin sensitivity. Total and high molecular adiponectin were not changed. Interestingly, serum leptin was significantly increased by 3 months Telmisartan treatment, suggesting a possible involvement of leptin in improved insulin sensitivity. In conclusion, Telmisartan improved insulin resistance with increased serum leptin level in hypertensive and type 2 diabetic patients.</description><identifier>ISSN: 0168-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2006.11.014</identifier><identifier>PMID: 17240472</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adiponectin - blood ; Adult ; Aged ; Aged, 80 and over ; Albuminuria - prevention & control ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; ARB ; Benzimidazoles - therapeutic use ; Benzoates - therapeutic use ; Blood Pressure - drug effects ; Body Mass Index ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Diabetic Angiopathies - drug therapy ; Diet, Diabetic ; Endocrinology & Metabolism ; Female ; HOMA-IR ; Humans ; Hypertension - drug therapy ; Hypoglycemic Agents - therapeutic use ; Leptin ; Leptin - blood ; Lipids - blood ; Male ; Middle Aged ; Telmisartan</subject><ispartof>Diabetes research and clinical practice, 2007-08, Vol.77 (2), p.210-214</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2007 Elsevier Ireland Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c418t-ac857449c53d231e92df03f6abd873d316384ac62cda74c6e26f5edfe075ea433</citedby><cites>FETCH-LOGICAL-c418t-ac857449c53d231e92df03f6abd873d316384ac62cda74c6e26f5edfe075ea433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.diabres.2006.11.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17240472$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Usui, Isao</creatorcontrib><creatorcontrib>Fujisaka, Shiho</creatorcontrib><creatorcontrib>Yamazaki, Katsuya</creatorcontrib><creatorcontrib>Takano, Atsuko</creatorcontrib><creatorcontrib>Murakami, Shiho</creatorcontrib><creatorcontrib>Yamazaki, Yu</creatorcontrib><creatorcontrib>Urakaze, Masaharu</creatorcontrib><creatorcontrib>Hachiya, Haruo</creatorcontrib><creatorcontrib>Takata, Michiyo</creatorcontrib><creatorcontrib>Senda, Satoko</creatorcontrib><creatorcontrib>Iwata, Minoru</creatorcontrib><creatorcontrib>Satoh, Akira</creatorcontrib><creatorcontrib>Sasaoka, Toshiyasu</creatorcontrib><creatorcontrib>AK, Norel Dim</creatorcontrib><creatorcontrib>Temaru, Rie</creatorcontrib><creatorcontrib>Kobayashi, Masashi</creatorcontrib><title>Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>Abstract Telmisartan, a new angiotensin II type 1 receptor blocker (ARB), was recently reported to stimulate PPARγ, and stronger effects of Telmisartan on insulin sensitivity has been expected than the class effect of ARB. In the present study, we examined the effects of Telmisartan on insulin sensitivity and adipokine levels in hypertensive and type 2 diabetic patients. Outpatients with both hypertension and type 2 diabetes mellitus ( n = 36; male 23, female 13), received 20–40 mg Telmisartan orally once daily for 6 months. Physical examinations and blood or urine tests were performed before and 3 or 6 months after starting Telmisartan treatment. Results were statistically compared using Wilcoxon analysis. Telmisartan treatment for 3 or 6 months reduced systolic and diastolic blood pressure and urinary albumin excretion. Fasting plasma glucose, HbA1c, total and HDL-cholesterol, triglyceride, body weight, BMI and waist length were not changed. Fasting IRI and HOMA-IR were significantly decreased after Telmisartan treatment, suggesting the improved insulin sensitivity. Total and high molecular adiponectin were not changed. Interestingly, serum leptin was significantly increased by 3 months Telmisartan treatment, suggesting a possible involvement of leptin in improved insulin sensitivity. In conclusion, Telmisartan improved insulin resistance with increased serum leptin level in hypertensive and type 2 diabetic patients.</description><subject>Adiponectin - blood</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Albuminuria - prevention & control</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>ARB</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Benzoates - therapeutic use</subject><subject>Blood Pressure - drug effects</subject><subject>Body Mass Index</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diabetic Angiopathies - drug therapy</subject><subject>Diet, Diabetic</subject><subject>Endocrinology & Metabolism</subject><subject>Female</subject><subject>HOMA-IR</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Leptin</subject><subject>Leptin - blood</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Telmisartan</subject><issn>0168-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1DAUha0K1E4fP6HIK3YJfiXObIqqCmilokrQri2PfUM99TjBdgbNir-O0xkJiQ2ra9nn3Ov7HYQuKakpoe2HdW2dXkVINSOkrSmtCRVHaEE7yaqOMfkGLYquez2foNOU1qQIuWiO0QmVTBAh2QL9fgS_cUnHrAOOYCcDFq_8MFg8luZpioB1sPj24et1dfcN_3L5GbtgIujkwg88ep02GnsYswulbMGXZ_y8GyFmCMlt9_5cLjDD858hO4NHnR2EnM7R2177BBeHeoaePn96vLmt7h--3N1c31dG0C5X2nSNFGJpGm4Zp7Bktie8b_XKdpJbTlveCW1aZqyWwrTA2r4B2wORDWjB-Rl6v-87xuHnBCmrsrUB73WAYUpKEtEslw0rwmYvNHFIKUKvxug2Ou4UJWomr9bqQF7N5BWlqpAvvneHAdNqA_av64C6CD7uBVDW3DqIKpmCoPB2EUxWdnD_HXH1TwfjXXBG-xfYQVoPUwyFoaIqMUXU9zn-OX0iS_KEMf4HJxmt9g</recordid><startdate>20070801</startdate><enddate>20070801</enddate><creator>Usui, Isao</creator><creator>Fujisaka, Shiho</creator><creator>Yamazaki, Katsuya</creator><creator>Takano, Atsuko</creator><creator>Murakami, Shiho</creator><creator>Yamazaki, Yu</creator><creator>Urakaze, Masaharu</creator><creator>Hachiya, Haruo</creator><creator>Takata, Michiyo</creator><creator>Senda, Satoko</creator><creator>Iwata, Minoru</creator><creator>Satoh, Akira</creator><creator>Sasaoka, Toshiyasu</creator><creator>AK, Norel Dim</creator><creator>Temaru, Rie</creator><creator>Kobayashi, Masashi</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070801</creationdate><title>Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients</title><author>Usui, Isao ; Fujisaka, Shiho ; Yamazaki, Katsuya ; Takano, Atsuko ; Murakami, Shiho ; Yamazaki, Yu ; Urakaze, Masaharu ; Hachiya, Haruo ; Takata, Michiyo ; Senda, Satoko ; Iwata, Minoru ; Satoh, Akira ; Sasaoka, Toshiyasu ; AK, Norel Dim ; Temaru, Rie ; Kobayashi, Masashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c418t-ac857449c53d231e92df03f6abd873d316384ac62cda74c6e26f5edfe075ea433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adiponectin - blood</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Albuminuria - prevention & control</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>ARB</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Benzoates - therapeutic use</topic><topic>Blood Pressure - drug effects</topic><topic>Body Mass Index</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diabetic Angiopathies - drug therapy</topic><topic>Diet, Diabetic</topic><topic>Endocrinology & Metabolism</topic><topic>Female</topic><topic>HOMA-IR</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Leptin</topic><topic>Leptin - blood</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Telmisartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Usui, Isao</creatorcontrib><creatorcontrib>Fujisaka, Shiho</creatorcontrib><creatorcontrib>Yamazaki, Katsuya</creatorcontrib><creatorcontrib>Takano, Atsuko</creatorcontrib><creatorcontrib>Murakami, Shiho</creatorcontrib><creatorcontrib>Yamazaki, Yu</creatorcontrib><creatorcontrib>Urakaze, Masaharu</creatorcontrib><creatorcontrib>Hachiya, Haruo</creatorcontrib><creatorcontrib>Takata, Michiyo</creatorcontrib><creatorcontrib>Senda, Satoko</creatorcontrib><creatorcontrib>Iwata, Minoru</creatorcontrib><creatorcontrib>Satoh, Akira</creatorcontrib><creatorcontrib>Sasaoka, Toshiyasu</creatorcontrib><creatorcontrib>AK, Norel Dim</creatorcontrib><creatorcontrib>Temaru, Rie</creatorcontrib><creatorcontrib>Kobayashi, Masashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Usui, Isao</au><au>Fujisaka, Shiho</au><au>Yamazaki, Katsuya</au><au>Takano, Atsuko</au><au>Murakami, Shiho</au><au>Yamazaki, Yu</au><au>Urakaze, Masaharu</au><au>Hachiya, Haruo</au><au>Takata, Michiyo</au><au>Senda, Satoko</au><au>Iwata, Minoru</au><au>Satoh, Akira</au><au>Sasaoka, Toshiyasu</au><au>AK, Norel Dim</au><au>Temaru, Rie</au><au>Kobayashi, Masashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2007-08-01</date><risdate>2007</risdate><volume>77</volume><issue>2</issue><spage>210</spage><epage>214</epage><pages>210-214</pages><issn>0168-8227</issn><eissn>1872-8227</eissn><abstract>Abstract Telmisartan, a new angiotensin II type 1 receptor blocker (ARB), was recently reported to stimulate PPARγ, and stronger effects of Telmisartan on insulin sensitivity has been expected than the class effect of ARB. In the present study, we examined the effects of Telmisartan on insulin sensitivity and adipokine levels in hypertensive and type 2 diabetic patients. Outpatients with both hypertension and type 2 diabetes mellitus ( n = 36; male 23, female 13), received 20–40 mg Telmisartan orally once daily for 6 months. Physical examinations and blood or urine tests were performed before and 3 or 6 months after starting Telmisartan treatment. Results were statistically compared using Wilcoxon analysis. Telmisartan treatment for 3 or 6 months reduced systolic and diastolic blood pressure and urinary albumin excretion. Fasting plasma glucose, HbA1c, total and HDL-cholesterol, triglyceride, body weight, BMI and waist length were not changed. Fasting IRI and HOMA-IR were significantly decreased after Telmisartan treatment, suggesting the improved insulin sensitivity. Total and high molecular adiponectin were not changed. Interestingly, serum leptin was significantly increased by 3 months Telmisartan treatment, suggesting a possible involvement of leptin in improved insulin sensitivity. In conclusion, Telmisartan improved insulin resistance with increased serum leptin level in hypertensive and type 2 diabetic patients.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>17240472</pmid><doi>10.1016/j.diabres.2006.11.014</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2007-08, Vol.77 (2), p.210-214 |
| issn | 0168-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70459952 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adiponectin - blood Adult Aged Aged, 80 and over Albuminuria - prevention & control Angiotensin II Type 1 Receptor Blockers - therapeutic use ARB Benzimidazoles - therapeutic use Benzoates - therapeutic use Blood Pressure - drug effects Body Mass Index Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - physiopathology Diabetic Angiopathies - drug therapy Diet, Diabetic Endocrinology & Metabolism Female HOMA-IR Humans Hypertension - drug therapy Hypoglycemic Agents - therapeutic use Leptin Leptin - blood Lipids - blood Male Middle Aged Telmisartan |
| title | Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T16%3A33%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telmisartan%20reduced%20blood%20pressure%20and%20HOMA-IR%20with%20increasing%20plasma%20leptin%20level%20in%20hypertensive%20and%20type%202%20diabetic%20patients&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Usui,%20Isao&rft.date=2007-08-01&rft.volume=77&rft.issue=2&rft.spage=210&rft.epage=214&rft.pages=210-214&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2006.11.014&rft_dat=%3Cproquest_cross%3E70459952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70459952&rft_id=info:pmid/17240472&rft_els_id=S0168822707000022&rfr_iscdi=true |